These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37526173)

  • 1. Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis.
    Rzepiński Ł; Kośliński P; Kowalewski M; Koba M; Maciejek Z
    Neurol Neurochir Pol; 2023; 57(5):414-422. PubMed ID: 37526173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle Quality of Knee Extensors Based on Several Types of Force in Multiple Sclerosis Patients with Varying Degrees of Disability.
    Portilla-Cueto K; Medina-Pérez C; Romero-Pérez EM; Núñez-Othón G; Horta-Gim MA; de Paz JA
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208639
    [No Abstract]   [Full Text] [Related]  

  • 4. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
    Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G
    Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of selected serum protein levels with the degree of disability and NEDA-3 status in multiple sclerosis phenotypes.
    Lamancová P; Urban P; Mašlanková J; Rabajdová M; Mareková M
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3933-3941. PubMed ID: 35731063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
    Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship of tryptophan metabolites with the type and severity of multiple sclerosis.
    Isık SMT; Onmaz DE; Ekmekci AH; Ozturk S; Unlu A; Abusoglu S
    Mult Scler Relat Disord; 2023 Sep; 77():104898. PubMed ID: 37481818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients-The Example of Croatia.
    Jerković A; Pavelin S; Šoda J; Vujović I; Rogić Vidaković M
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national registry-based study of ethnic differences in people with multiple sclerosis in Iran.
    Ashtari F; Kavosh A; Baghbanian SM; Hosseini Nejad Mir N; Hosseini S; Razazian N; Majdinasab N; Farajzadegan Z; Shaygannejad V; Adibi I; Eskandarieh S; Sahraian MA
    Clin Neurol Neurosurg; 2024 Apr; 239():108216. PubMed ID: 38490075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
    Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
    Dickens AM; Larkin JR; Griffin JL; Cavey A; Matthews L; Turner MR; Wilcock GK; Davis BG; Claridge TD; Palace J; Anthony DC; Sibson NR
    Neurology; 2014 Oct; 83(17):1492-9. PubMed ID: 25253748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and relation of two arm function tests, Box and Blocks test and Nine Hole Peg test, across disease severity levels and types of multiple sclerosis.
    Bertoni R; Cattaneo D; Grosso C; Baglio F; Jonsdottir J
    Mult Scler Relat Disord; 2022 Mar; 59():103683. PubMed ID: 35168094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors.
    Etemadifar M; Salari M; Esnaashari A; Ghazanfaripoor F; Sayahi F; Akhavan Sigari A; Sedaghat N
    Mult Scler Relat Disord; 2022 Feb; 58():103488. PubMed ID: 34999375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assessment of people with relapsing-remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization-Results of a large-scale cross-sectional online survey (MS Perspectives).
    Bayas A; Schuh K; Christ M
    Mult Scler Relat Disord; 2022 Dec; 68():104166. PubMed ID: 36115289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.